Purpose: To know influence of artificial tear related with conjunctival goblet cell density in glaucoma patient with latanoprost therapy. Method: Pre-posttest design with expanded randomized study. This study was performed at Eye Policlinic Sanglah Public Hospital Denpasar and Bali Mandara Hospital from October until December 2015. Forty eyes were taken for impression cytology specimen to search goblet cell density before and 30 days after therapy. Mean difference of goblet cell changes before and after therapy between case and control analyzed with independent t-test. Results: There were enhancements of conjunctival goblet cell mean density on group with artificial tear before and after therapy 83 + 97 cell/mm² to 92 + 88 cell/mm². There was reduction of conjunctival goblet cell mean density of group without artificial tear from 144 + 169 cell/mm² to 78 + 103 cell/mm².Mean difference between both group in this study differ not significant statistically (p=0,178). However, mean difference of conjunctival goblet cell density before and after therapy between both groups differ -75+ 54 cell/mm². Conclusions: Artificial tears have a considerable effect (important), although not statistically significantly.

Darhad U, Nakamura M, Fujioka M, Tatsumi Y, Nagai-Kusuhara A, Maeda H, et al. Intraocular Pressure Lowering Effect of Once Daily versus Once Weekly Latanoprost Instillation in the Same Normal Individuals. Kobe Journal Medicine Sci. 2007;53(6):297-304.

Aquino MV, Lat-Luna M. The Effect of Latanoprost vs Timolol on Intraocular Pressure in Patients with Glaucoma and Ocular Hypertension. Asian Journal Of Ophthalmology. 1999;1(3):3-7.

Russo A, Riva I, Pizzolante T, Noto F, Quaranta L. Latanoprost Ophthalmic Solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clinical Ophthalmology. 2008;897-905.

Kahook MY, Noecker R. Quantitative Analysis of Conjunctival Goblet Cells after Chronic Application of Topical Drops. Advanceds in therapy. 2008;743-51.

MastropasquaL, Agnifili L, Fasanella V, Curcio C, Cristina C, Mastropasqua R, et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmologica Scandinavica Foundation. 2013;397-405.

Costa VP, Silva RS, Anbrosic R. The need for artificial tears in glaucoma patients: a comparative, retrospective study. Arg Bras Oftalmol. 2013;6-9.

Bhargava R, KumarP, Kaur A, Kumar M, Mishra A. The Diagnostic Value and Accuracy of Conjunctival Impression Cytology, Dry Eye Symptomatology, and Routine Year Function Tests in Computer Users. 2014.

Tong L, Petznick A, Lee S, Tan J. Choice of Artificial Tear Formulation for Patients With Dry Eye: Where Do We Start?. Cornea Journal. 2012;31(10):33-6.

American Academy of Ophthalmology and Staff. Fundamentals and Principles of Ophthalmology. United State of America: American Academy of Opthalmology.2014-2015;217.

Demiryay E, Yaylali V, Cetin EN, Yildirim C. Effects of Topical Cyclosporine A Plus Artificial Tears Versus Artificial Tears Treatment on Conjunctival Goblet Cell Density in Dysfunctional Tear Syndrome. Eye & Contact Lens. 2011;37(5):312-5.

Abu-Amero KK, Kondkar AA, Mousa A, Osman EA, Al-Obeidan SA. Association of Mn-SOD Mutation (c.47T>C) with Various POAG Clinical Indices. Ophthalmic Genetics, Early Online, Informa Healthcare USA.2013;1-6.

Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle galucoma and ocular hypeetension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmologica. 2010;12-9.

Kwon YH, Fingert JH, Kuehn MH, Alward WLM.Mechanisms of Disease Primary Open-Angle Glaucoma. The New England Journal Of Medicine. 2009;1113-24.

Kamal D, Hitchings R. Normal tension glaucoma-a practical approach. British Journal Ophthalmology. 1998;82:835-40.

Gutteridge IF. Normal tension glaucoma: diagnostic features and comparisons with primary open angle glaucoma. Clinical and Experimental Optometry. 2000;83(3):161-72.

Actis AA, Rolle T. Ocular Surface Alterations and Topical Antiglaucomatous Therapy: A Review. The Open Ophthalmology Journal. 2014;8:67-72.

Povoa CA, Malta RFS, Rezende MM, Melo KFS, Giannella-Neto D. Correlation between genotype ad phenotype in primary open angle glaucoma of Brazilian families with mutations in exon 3 of the TIGR/MYOC gene. Arq Bras Oftalmol. 2006;69(3):289-97.

Suzuki M, Mishima HK, Masuda K, Araie M, Kitazawa Y, Azuma I. Efficacy and Safety of Latanoprost Eye Drops for Glaucoma Treatment:A 1-Year Study in Japan. Japan Journal of Ophthalmology. 2000;44:33-8.

Courtright P. Gender and Glaucoma in Primary Open Angle Glaucoma: everyone’s business. Community Eye Health Journal. 2012;25(79&80):45.

Denis P, Baudouin C, Bron A, Nordmann J, Renard JP, Rouland JF, Sellem E, Amrane M. First-line latanoprost therapy in ocular hypertension or open – angle glaucoma pateints: a 3-month efficacy ananlysis stratified by initial intraocular pressure. BMC Ophthalmology. 2010;10(4):1471-2415.

Anderson DR. Normal-tension galucoma (Low-tension glaucoma). Indian Journal Ophthalmology.2011.

Pepperl JE, Ghuman T, Gill KS, Zieske JD, Trocme SD. Duane’s Ophthalmology. Lippincott Williams & Wilkins. 2006.

Moore JE, Moore CBT. Dry Eye Testing in Glaucoma. View on Glaucoma. 2012;7(1):13-7.

Pflugfelder S, Bonini S, Messmer E, Nichols K, Simmons P. Role of Artificial Tears in Dry Eye Therapy. Allergan, Inc., Irvine, CA, USA. 2009.

Ehrenberg M, Zolotariov E, Loeb E, Poliansky V, Levy A. Combining Sodium Hyaluronate and Polyvinylpyrrolidone Therapies for the Rabbit Cornea: A New Approach to Relief of the Human Dry Eye Syndrome. Current Eye Research, Early Online. 2014;1-10.